Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00245765
Status:
COMPLETED
Last Update Posted:
2019-05-03
First Post:
2005-10-26
Brief Title:
Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy andor PhototherapyPhotochemotherapy
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
Multicenter Dose Response Randomized Double Blind Parallel Placebo Controlled Clinical Trial to Evaluate the Efficacy and the Safety of Subcutaneous CDP870 in Subjects Suffering From Moderate-to-severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy andor Phototherapy andor Photochemotherapy
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo administered during 12 weeks to patients suffering from moderate to severe chronic plaque psoriasis extended by a 12 to 24 week follow-up
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-002141-39 | EUDRACT_NUMBER | None | None |